uniQure (QURE) reported a third-quarter loss of $0.88 per share, $0.04 worse than the -$0.84 consensus, a 4.8% miss. Revenue of $5.2 million fell 27.3% short of the $7.15 million estimate. Year over year, earnings improved 36.2% from a $1.38 loss, and revenue grew 40.4% on higher license income. For a company whose value rests almost entirely on one Huntington's disease gene therapy, the quarterly numbers are secondary. The real development is regulatory. The FDA accepted the BLA for AMT-130 (ifezuntirgene inilparvovec) under the Accelerated Approval pathway with Priority Review, setting a PDUFA date of May 1, 2027. The central tension is that this regulatory progress has arrived while the stock has fallen more than a third since the last report, and the call raised new questions about how cleanly the path to approval will run.

The narrower loss deserves some scrutiny. Net loss improved to $61.2 million from $80.5 million, but operations did not drive that improvement.

• **Operating loss widened** slightly, to $53.0 million from $51.0 million.
• **SG&A rose** to $23.9 million from $19.4 million as the company hired ahead of launch.
• **R&D edged up** to $35.5 million.
• **Non-operating items supplied the gain.** Pre-funded warrant expense fell $6.3 million, net interest income improved $6.8 million, and income tax expense dropped to $0.7 million from $8.6 million.
• **Dilution flattered the per-share figure.** Weighted shares rose to 69.9 million from 58.5 million.

Revenue also slipped sequentially from $5.8 million in Q2. Cash fell to $768.4 million from $810.3 million at the end of June, roughly $42 million of quarterly consumption. That balance is still well above the $622.5 million at year-end 2025 after a follow-on financing, and management reaffirmed a runway into 2030.

The call completed a striking regulatory arc. As recently as the March call, the FDA was recommending a randomized, sham-controlled Phase 3. The company then secured agreement in July that three-year data could support accelerated approval. It now has an accepted, priority-review BLA and a validated UK MAA. Management also aligned with the FDA on a confirmatory study:

• roughly 200 patients;
• 2:1 randomization against standard of care;
• Total Functional Capacity as the primary endpoint at 36 months;
• protocols submitted to U.S. IRBs, with screening targeted by year-end.

Commercial preparation has become concrete. Management expects more than 15, and potentially 25 to 30, treatment centers at launch, a core commercial team in place in early 2027, and no manufacturing constraint.

Bears still have legitimate ammunition. The September 48-month update showed a 44% slowing on the pre-specified cUHDRS endpoint against an updated external control, but that result was not statistically significant (p=0.144). The more supportive TFC result (61% slowing, nominal p=0.008) and the 36-month analysis of all 15 high-dose patients (80% slowing on cUHDRS) carry only nominal significance. The call also introduced several new risks:

• **Advisory committee.** The FDA is tentatively planning one.
• **Confirmatory timing.** The agency expects the confirmatory study to be "well underway" at approval, yet screening begins only about four months before the PDUFA date.
• **Possible delay.** A request for four-year data could trigger a major amendment and push back the action date.
• **Trial integrity.** Patients in the standard-of-care arm may drop out once the product is commercially available.
• **Launch pace.** Uptake will be gated by treatment-center capacity, P&T approvals and payer access.

In the pipeline, AMT-260's second epilepsy cohort is fully enrolled, but the low-dose signal was mixed, with 3 of 6 patients responding. AMT-191 dosing in Fabry disease resumed after a liver-enzyme pause. Both programs read out in the first half of 2027.

The market has been unforgiving. Shares opened at $38.00 after the July report and spiked to a 52-week high of $51.72 on August 25. They then slid to an inter-earnings low of $20.33 on October 14, a collapse that followed the September data release. At $23.87, the stock sits 53.8% below that peak, 17.4% above the low and 19.4% below its 200-day moving average of $29.63. Price and AVWAP trend readings remain negative, although momentum has turned positive off the October trough. Investor sentiment stayed marginally positive but softened slightly, to 0.019 from 0.037. That reading reflects near-neutral expectations rather than conviction in either direction.

The bottom line is that uniQure's double miss is largely noise for a pre-commercial company, and its narrower loss owes more to non-operating items and dilution than to cost discipline. What matters is that AMT-130 now has a dated FDA decision, a funded runway into 2030 and an agreed confirmatory design. The stock's halving from its August high shows investors are discounting the statistical fragility of the data, a likely advisory committee and tight confirmatory-trial timing. The setup over the next six months hinges on regulatory execution rather than quarterly financials.